Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 gene mutations in multiple myeloma

R G Owen1, S A Davis, J Randerson

  • 1Centre for Haematological Oncology, General Infirmary at Leeds.

Molecular Pathology : MP
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.

Blood cancer journal·2024
Same author

Realist analysis of whether emergency departments with primary care services generate 'provider-induced demand'.

BMC emergency medicine·2022
Same author

Arctic and boreal ecosystems of western North America as components of the climate system.

Global change biology·2022
Same author

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.

Leukemia·2021
Same author

Adverse childhood experiences among early care and education teachers: Prevalence and associations with observed quality of classroom social and emotional climate.

Children and youth services review·2020
Same author

Clinical risk stratification and antibiotic management of NDM and OXA-48 carbapenemase-producing Enterobacteriaceae bloodstream infections in the UK.

The Journal of hospital infection·2019
Same journal

Development of molecular methods for the identification of aspergillus and emerging moulds in paraffin wax embedded tissue sections.

Molecular pathology : MP·2003
Same journal

Tempero-spatial dissociation between the expression of Fas and apoptosis after coronary occlusion.

Molecular pathology : MP·2003
Same journal

Inverse correlation between high level expression of cyclin E and proliferation index in transitional cell carcinoma of the bladder.

Molecular pathology : MP·2003
Same journal

Nuclear beta catenin as a potential prognostic and diagnostic marker in patients with colorectal cancer from Hong Kong.

Molecular pathology : MP·2003
Same journal

Increased cyclin D1 expression in cancer of the ampulla of Vater: relevance to nuclear beta catenin accumulation and k-ras gene mutation.

Molecular pathology : MP·2003
Same journal

Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.

Molecular pathology : MP·2003
See all related articles

p53 gene mutations are rare in multiple myeloma, occurring in only 3.2% of patients. These mutations appear to have limited value as a prognostic factor in multiple myeloma progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Multiple myeloma is a cancer of plasma cells.
  • The p53 tumor suppressor gene plays a critical role in preventing cancer development.

Purpose of the Study:

  • To investigate the role of p53 gene mutations in the development and progression of multiple myeloma.

Main Methods:

  • Examined 38 DNA samples from 31 multiple myeloma patients for p53 mutations in exons 5-9.
  • Utilized polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) for mutation detection.

Main Results:

  • A single p53 mutation (3.2%) was identified in an exon 6 of a diagnostic bone marrow sample.
  • The mutation was a silent A to G transition at codon 213, a known polymorphism.

Related Experiment Videos

Conclusions:

  • p53 gene mutations are infrequent in multiple myeloma.
  • p53 mutations have limited utility as prognostic indicators in this disease.